B ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for B ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new B ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for B ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising new combo aims to beat aggressive leukemia
Disease control Recruiting nowThis phase 2 trial is testing a combination of blinatumomab (an immune-boosting drug) with dasatinib or imatinib (targeted pills) and standard chemotherapy for people with a specific type of leukemia called Philadelphia chromosome-positive or Philadelphia chromosome-like B-ALL. T…
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to beat tough childhood leukemia
Disease control Recruiting nowThis phase 3 trial tests whether adding the targeted drug inotuzumab ozogamicin to standard chemotherapy and immunotherapy improves outcomes for children and young adults with high-risk B-cell acute lymphoblastic leukemia (B-ALL). The study will enroll about 6,000 participants an…
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Promising new combo therapy for infant leukemia shows potential
Disease control Recruiting nowThis study tests whether adding two targeted drugs, blinatumomab and venetoclax, to standard chemotherapy can improve outcomes for infants with a type of leukemia called acute lymphoblastic leukemia (ALL). About 153 infants will participate. The goal is to see if these combinatio…
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New hope for kids with tough leukemia: targeted Antibody-Drug combo shows promise
Disease control Recruiting nowThis study tests a drug called inotuzumab ozogamicin in children and young adults (ages 1 to 21) whose B-cell acute lymphoblastic leukemia (B-ALL) has returned or not responded to standard treatment. The drug works like a guided missile, attaching to a marker (CD22) on cancer cel…
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New combo therapy aims to beat leukemia in young adults
Disease control Recruiting nowThis phase III trial is testing whether adding inotuzumab ozogamicin—a drug that targets cancer cells—to standard chemotherapy can improve outcomes for young adults (ages 18-39) newly diagnosed with B-cell acute lymphoblastic leukemia. About 310 participants will be enrolled. The…
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Promising combo therapy aims to beat B-ALL without transplant
Disease control Recruiting nowThis phase II trial is testing whether adding two immunotherapy drugs (blinatumomab and inotuzumab ozogamicin) to a standard chemotherapy regimen (Hyper-CVAD) can improve outcomes for adults newly diagnosed with B-cell acute lymphoblastic leukemia (B-ALL). The study plans to enro…
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New combo therapy aims to wipe out leukemia in adults who Can't take standard treatment
Disease control Recruiting nowThis study tests a combination of chemotherapy drugs (DA-EPOCH) plus an enzyme called asparaginase (Rylaze) in adults newly diagnosed with a fast-growing blood cancer (Philadelphia chromosome-negative ALL). The goal is to see if this mix can kill more cancer cells and achieve dee…
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Experimental CAR T-Cell therapy targets tough blood cancers
Disease control Recruiting nowThis early-phase study tests a new type of CAR T-cell therapy for adults with blood cancers like leukemia, lymphoma, and multiple myeloma that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and attack canc…
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Can we safely use less blood for leukemia patients?
Knowledge-focused Recruiting nowThis study looks at whether giving blood transfusions only when hemoglobin drops below 7 gm/dL (instead of 9 gm/dL) is safe and maintains quality of life in leukemia patients after chemotherapy or stem cell transplant. About 50 adults with certain blood cancers will be randomly a…
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: NA • Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Scientists hunt for relapse clues in childhood leukemia
Knowledge-focused Recruiting nowThis study looks at why 20% of children with B-cell acute lymphoblastic leukemia (B-ALL) relapse after treatment. Researchers will collect bone and blood samples from 50 newly diagnosed children at three key points during therapy. They will study how a protein called CD9 is regul…
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: NA • Sponsor: Rennes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC